Evidence map›Paper›PMID 39359767›Full record

ArticleAnnals of medicine and surgery (2012)2024

Clinical outcomes following hospitalization for COVID-19 in patients with cardiac sarcoidosis in the United States: a propensity-matched analysis from national inpatient sample database from April 2020 to December 2021.

Sebastian Mactaggart, Raheel Ahmed, Asma Riaz, Shehroze Tabassum, Kamleshun Ramphul, Maham Bilal, Yumna Jamil, Mansimran Singh Dulay, Alexander Liu, Mushood Ahmed and 7 more

Abstract read
In one paragraph

Article in Annals of medicine and surgery (2012), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Sebastian MactaggartNorthumbria Healthcare NHS Foundation Trust, Newcastle.ORCID https://orcid.org/0009-0000-7039-4269
Raheel AhmedCardiac Sarcoidosis Services, Royal Brompton Hospital.
Asma RiazDow University of Health Sciences, Karachi.
Shehroze TabassumKing Edward Medical University, Lahore.
Kamleshun RamphulIndependent Researcher, Mauritius.
Maham BilalDow University of Health Sciences, Karachi.
Yumna JamilDow University of Health Sciences, Karachi.
Mansimran Singh DulayCardiac Sarcoidosis Services, Royal Brompton Hospital.
Alexander LiuCardiac Sarcoidosis Services, Royal Brompton Hospital.
Mushood AhmedRawalpindi Medical University, Rawalpindi, Pakistan.
Hiroyuki SawatariHiroshima University, Hiroshima, Japan.
Prince K Pekyi-BoatengKorle Bu Teaching Hospital, Accra, Ghana.ORCID https://orcid.org/0000-0002-7206-6207
Alessia AzzuCardiac Sarcoidosis Services, Royal Brompton Hospital.
Athol WellsCardiac Sarcoidosis Services, Royal Brompton Hospital.
Vasilis KouranosCardiac Sarcoidosis Services, Royal Brompton Hospital.
Anwar ChahalDepartment of Cardiology, Barts Heart Centre, London, UK.
Rakesh SharmaCardiac Sarcoidosis Services, Royal Brompton Hospital.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The highly arrhythmogenic nature of cardiac sarcoidosis (CS) leads to high morbidity and mortality, the rates of which may be higher in COVID-19 patients. This study aimed to evaluate the outcomes of CS patients admitted to hospitals with COVID-19. Methods: The study utilised the 2020-2021 National Inpatient Sample database, examining primary COVID-19 cases in adults aged older than or equal to 18 years. Those with CS were identified using ICD-10 code "D86.85" and compared with and without propensity matching (1:10) to those without CS for baseline characteristics and primary outcomes of acute kidney injury (AKI), use of mechanical ventilation, cardiac arrest and mortality. Results: In total, 2 543 912 COVID-19 cases were identified. Before propensity matching, CS patients were more likely to be younger (58.0 vs. 64.0 years, Conclusion: In a propensity-matched cohort admitted with COVID-19, CS patients had a reduced risk of AKI, but comparable LOS, rates of cardiac arrest, mechanical ventilator use, and mortality. Future research is warranted to develop evidence-based guidelines for managing COVID-19 in patients with CS.

Indexed as

cardiac sarcoidosiscovid-19NISpropensity matchingsarcoidosis

Identifiers

PMID39359767
PMCPMC11444656

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.